OCC 20.9% 66.5¢ orthocell limited

Reminder - J&J ATI Rotator Cuff clinical trial update coming soon, page-5

  1. 1,666 Posts.
    lightbulb Created with Sketch. 178
    As everyone else I appreciate your knowledgeable input bedger.

    I have one genuine concern. Are there any, or do you or does anyone else know of alternative procedures that could be in direct
    competition to Celgro and ATI/ACI in the short to medium term?

    I know that Celgro has established competition in the dental bone graft field (albeit not as effective).

    There is just this nagging thought in the back of my mind that there are alternatives therapies out there and that is why OCC can't gain much traction in the market or the medical profession.

    I assure you I am not trying to downramp.I have too much invested in this company. This is really the only real concern I have about OCC.

    Any other problems on the horizon will take care of themselves (with good management of course), because we have such remarkable products.

    Cheers everyone.





 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.